Journal of traumatic stress
August 1, 2021
Linnae Ponte, Lisa Jerome, Scott Hamilton et al.
42 citations
Sleep disturbances are common and hard to treat in PTSD. In four randomized controlled double-blind studies, 63 participants received either active MDMA (75-125 mg) or placebo/control MDMA (0-40 mg) during psychotherapy sessions. At the primary endpoint 1-2 months after sessions, PTSD symptoms dropped more with active MDMA than placebo (CAPS-IV score change -34.0 vs. -12.4). Sleep quality also improved more with active MDMA (PSQI score change -3.5 vs. +0.6). Sleep quality continued to improve from treatment exit to 12-month follow-up. These data provide evidence that MDMA-assisted psychotherapy benefits sleep disturbances in PTSD.
Journal of traumatic stress
May 7, 2025
Mark Creamer, Richard Bryant, Amy Lehrner et al.
1 citation
A panel of clinicians and researchers at the 2024 ISTSS annual meeting discussed psychedelic-assisted psychotherapy for PTSD. Despite diverse views, they largely agreed the approach is an exciting possibility for patients who have not responded to existing evidence-based treatments. However, they also agreed that considerably more rigorous research is needed before definitive conclusions about its components and efficacy can be drawn. Ethical concerns, especially regarding accessibility, will pose a significant challenge for provider organizations.
Journal of traumatic stress
June 1, 2026
Kadek Suhardita, Veno Dwi Krisnanda, Rikas Saputra et al.
MDMA-assisted psychotherapy shows promise for treating PTSD, but the evidence base has major limitations: difficulties in blinding, expectancy effects, lack of active comparators, unclear mechanisms, and safety concerns. The commentary argues these issues are central to interpreting the therapy's effects and future translation. It calls for moving beyond symptom reduction to broader recovery indicators like functioning, quality of life, relational restoration, and long-term durability. Stronger attention to equity, scalability, therapist training, and ethical safeguards is needed, especially for global mental health frameworks. The discussion aims to stimulate deeper debate on evaluating innovation in trauma treatment before widespread clinical adoption.